The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells

被引:260
作者
Asano, T [1 ]
Yao, YX [1 ]
Zhu, JJ [1 ]
Li, DH [1 ]
Abbruzzese, JL [1 ]
Reddy, SAG [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
关键词
pancreatic cancer; PI; 3-kinase; Akt; NF-kappa B; c-Myc; PTEN;
D O I
10.1038/sj.onc.1207902
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The persistent activation of signaling cascades results in dramatic consequences that include loss of cellular growth control and neoplastic transformation. We show here that phosphoinositide 3-kinase (PI 3-kinase) and its mediator Akt were constitutively activated in pancreatic cancer and that this might be due to the aberrant expression of their natural antagonist MMAC/PTEN. Indeed, our results show that MMAC/PTEN expression was either lost or significantly reduced in five of eight cell lines and in twelve of seventeen tumor specimens examined. That the poor expression of MMAC/PTEN in pancreatic cancer cells could be due to promoter methylation was indicated by methylation-specific PCR analysis. Our studies also indicated that PI 3-kinase targeted two important transcription factors in pancreatic cancer cells. The ability of constitutively activated NF-kappaB to induce gene expression and the stabilization of c-MYC protein by decreased phosphorylation of Thr58 were both dependent on PI 3-kinase activity. When pancreatic cancer cells were treated with a peptide antagonist of NF-kappaB nuclear translocation, or stably transfected with a dominant-negative mutant of MYC, their proliferation was markedly inhibited. Taken together, these data indicate that the aberrant expression of MMAC/PTEN contributes to the activation of the PI 3-kinase/Akt pathway and its transcription factor mediators in pancreatic cancer.
引用
收藏
页码:8571 / 8580
页数:10
相关论文
共 57 条
[21]  
Kolenko V, 1999, J IMMUNOL, V163, P590
[22]   Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFκB activation without interfering with the IκB degradation pathway [J].
Koul, D ;
Yao, YX ;
Abbruzzese, JL ;
Yung, WKA ;
Reddy, SAG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) :11402-11408
[23]   PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J].
Li, J ;
Yen, C ;
Liaw, D ;
Podsypanina, K ;
Bose, S ;
Wang, SI ;
Puc, J ;
Miliaresis, C ;
Rodgers, L ;
McCombie, R ;
Bigner, SH ;
Giovanella, BC ;
Ittmann, M ;
Tycko, B ;
Hibshoosh, H ;
Wigler, MH ;
Parsons, R .
SCIENCE, 1997, 275 (5308) :1943-1947
[24]   CURRENT MANAGEMENT OF PANCREATIC-CARCINOMA [J].
LILLEMOE, KD .
ANNALS OF SURGERY, 1995, 221 (02) :133-148
[25]   Molecular pathology of invasive carcinoma [J].
Longnecker, DS .
CELL AND MOLECULAR BIOLOGY OF PANCREATIC CARCINOMA: RECENT DEVELOPMENTS IN RESEARCH AND EXPERIMENTAL THERAPY, 1999, 880 :74-82
[26]   The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate [J].
Maehama, T ;
Dixon, JE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (22) :13375-13378
[27]   Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane [J].
Maira, SM ;
Galetic, I ;
Brazil, DP ;
Kaech, S ;
Ingley, E ;
Thelen, M ;
Hemmings, BA .
SCIENCE, 2001, 294 (5541) :374-380
[28]   Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo [J].
Mills, GB ;
Lu, YL ;
Kohn, EC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10031-10033
[29]   Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers [J].
Mutter, GL ;
Lin, MC ;
Fitzgerald, JT ;
Kum, JB ;
Baak, JPA ;
Lees, JA ;
Weng, LP ;
Eng, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11) :924-931
[30]  
Nagy A, 2001, ANTICANCER RES, V21, P1321